Company / Capital Expenditures
Phathom Pharmaceuticals, Inc. Capital Expenditures History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Expenditures
$229.0K
FY2025
5-year range
$229.0K / $1.6M
FY2021-FY2025
Trend
-86.0%
vs FY2024
Sector context
#155 of 194
Health Care
What the data says
Phathom Pharmaceuticals, Inc.'s capital expenditures of $229,000 is lower than 80% of companies in the Health Care sector (FY2025). Declined from $2M to $229,000 over the past 2 years.
Based on SEC 10-K filings.
$229,000 in FY2025 with a 5-year CAGR of -26.1%.
Declined from $2M to $229,000 over the past 2 years.
Health Care sector context is included.
Capital Expenditures over time
Growth rates
- 3-Year CAGR
- -39.6%
- 5-Year CAGR
- -26.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 20% in Health CareTop 80% of 194This company $229.0K Sector average $117.5M
▼
-99.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -26.1%, indicating a declining trend.
- In FY2025, capital expenditures decreased 86.0% year-over-year.
- Ranks #155 out of 194 companies in the Health Care sector.
- Peak capital expenditures was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -6.09 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital ExpendituresValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $229.0K | -86.0% |
| FY2024 | $1.6M | +0.0% |
| FY2023 | $1.6M | +57.0% |
| FY2022 | $1.0M | +217.4% |
| FY2021 | $328.0K | -68.5% |
| FY2020 | $1.0M | +687.9% |
| FY2019 | $132.0K | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026